Home » Newsletters » BioWorld Science

BioWorld Science

July 14, 2021

View Archived Issues

Patient recruitment ongoing in two phase I/II trials of TQ-05105 in GvHD

Enrollment ongoing in phase II study of ISA-101b vaccine plus cemiplimab in HPV16 cervical cancer

Tyrosine-protein kinase ITK/TSK inhibitors discovered at Pfizer

Roche, Monash University describe IL-37 fusion proteins

Genfit presents prodrugs of nuclear receptor ROR-gamma modulators

Janssen Pharmaceutica discovers menin/MLL interaction inhibitors

ERK-1/2 inhibitor GIZH298 demonstrates antiseizure effects in vivo

VRG-101: a new PIKfyve inhibitor for SARS-CoV-2

AR-712 MAb cocktail neutralizes SARS-CoV-2 Delta variant

Ionis and Bicycle Therapeutics enter licensing agreement to advance LICA technology

miR-491-5p and miR-592 are downregulated in overactive bladder

PAT-DX3 shows the ability to cross blood-brain barrier in models of GBM

Hepion reports phase IIa topline data on CRV-431 in presumed F2 and F3 NASH

Genocea initiates phase I/IIa study of neoantigen-targeted T cell therapy GEN-011

XVR-011 shows neutralization activity against the Gamma and Delta variants of SARS-CoV-2

ACE2 and TLR7 are highly expressed in severe patients with COVID-19

SFX-01 shown to be effective in in vitro models of blood cancers

First cohort of subjects dosed in ASC-42 bridging study in China

FDA clears IND for Kintor's GT-20029 for androgenetic alopecia and acne

Barcoding strategy tracks breast cancer metastases

ENA studies INNA-051 nasal spray in phase I to boost innate immunity against respiratory viruses

TP-03 enhances the stimulating effect of hCG on testicular steroidogenesis

Oryzon cleared to begin phase IIb trial of vafidemstat in schizophrenia

Valo submits CTA for first-in-human study of PeptiCRAd-1 in melanoma, TNBC and NSCLC

Oral fadraciclib enters phase I/II study in advanced solid tumors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...